The pharmaceutical and medical technology industries appear to show marked transfer of value variations in this year’s Open Payments data. This study investigates further and asks, is it a case of two sectors using unique commercial models, or a simple case of different reporting methodologies?
For many years now, the medical technology industry (Medtech) has maintained that it is distinct from the pharmaceutical industry (Pharma) despite being subject to much of the same legal and compliance requirements. This is true with respect to the Physician Payments Sunshine Act (i.e., Open Payments).
Related Posts
Read Full Article in the September 2016 Issue of Life Science Compliance Update